The Evolution of the Use of β-Blockers to Treat Heart Failure: A Conversation With Finn Waagstein, MD.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 28874420.
- Also identified by DOI 10.1161/CIRCULATIONAHA.117.029934.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Finn Waagstein was born in Copenhagen in 1938. He graduated from Aarhus University Medical School in 1964. He received his cardiology training in the Sahlgrenska University Hospital at the University of Gothenburg, Sweden. He was appointed Associate Professor in 1980, and he assisted in establishing and directing the first Swedish heart transplant program. From 1990 he directed the heart failure and cardiomyopathy research programs. He is currently Professor of Cardiology and senior physician at Wallenberg Laboratory. In 2002, he was awarded the King Faisal International Prize for Medicine.
Medical subject headings
- Adrenergic beta-Antagonists
- Heart Failure